These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15663072)

  • 1. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
    Grimes PE
    Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation.
    Cook-Bolden FE; Hamilton SF
    Cutis; 2008 Apr; 81(4):365-71. PubMed ID: 18491487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
    Kaufman BP; Alexis AF
    J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
    Grimes PE
    Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
    J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
    Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
    Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based trial of a triple-combination agent for the treatment of facial melasma.
    Grimes P; Kelly AP; Torok H; Willis I
    Cutis; 2006 Mar; 77(3):177-84. PubMed ID: 16610738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
    Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M
    J Cosmet Dermatol; 2007 Mar; 6(1):36-9. PubMed ID: 17348994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
    J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
    J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
    Bruce S
    J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postinflammatory hyperpigmentation: evolving combination treatment strategies.
    Taylor SC; Burgess CM; Callender VD; Fu J; Rendon MI; Roberts WE; Shalita AR
    Cutis; 2006 Aug; 78(2 Suppl 2):6-19. PubMed ID: 16977792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved quality of life with effective treatment of facial melasma: the pigment trial.
    Balkrishnan R; Kelly AP; McMichael A; Torok H
    J Drugs Dermatol; 2004; 3(4):377-81. PubMed ID: 15303781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and efficacy of a novel formulation in the treatment of melasma.
    Guevara IL; Werlinger KD; Pandya AG
    J Drugs Dermatol; 2010 Mar; 9(3):215-8. PubMed ID: 20232581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
    Serra M; Bohnert K; Narda M; Granger C; Sadick N
    J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma.
    Guevara IL; Pandya AG
    Int J Dermatol; 2003 Dec; 42(12):966-72. PubMed ID: 14636195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma.
    Tirado-Sánchez A; Santamaría-Román A; Ponce-Olivera RM
    Int J Dermatol; 2009 Aug; 48(8):893-5. PubMed ID: 19659872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of two formulations containing diacetyl boldine, TGF-β1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin.
    Pratchyapurit WO
    J Cosmet Dermatol; 2016 Jun; 15(2):131-44. PubMed ID: 26833454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Fabi SG
    Dermatol Surg; 2018 Oct; 44(10):1304-1310. PubMed ID: 29659405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical treatments for melasma and postinflammatory hyperpigmentation.
    Lynde CB; Kraft JN; Lynde CW
    Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.